SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma – Testing, Treatment, and Supportive Care

HER2-positive gastroesophageal adenocarcinoma demands precise, sequential decision-making-from complete molecular profiling at diagnosis through first-line selection, progression, rebiopsy, and later-line therapy. Persistent gaps include incomplete biomarker testing at baseline, selecting among evolving first-line regimens, recognizing and managing treatment-related diarrhea early enough to preserve dose intensity, identifying drug-related interstitial lung disease (ILD) promptly and initiating appropriate therapy, and communicating complex plans in language patients can act on. This SimulatED(TM) online, on-demand program follows a single patient case through physician-patient dialogues, interactive patient interviews, multiple-choice decision points, and expert commentary to translate evidence into practice. Learners confirm the molecular profile and select first-line therapy; recognize and manage grade 2 diarrhea; respond to disease progression with rebiopsy and second-line selection; manage treatment-related ILD; and choose third-line therapy. Immediate expert feedback at each decision point, paired with modeled teach-back and shared decision-making, builds both clinical judgment and communication skills.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

Case study / clinical scenario
includes On-demand / recorded video
Credit · Up to 1 credit
Commercial Support

Released

Jul 31, 2026
Last day to claim credit

Aug 1, 2027 10 months left

SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma – Testing, Treatment, and Supportive Care

More from Physicians’ Education Resource

Related courses